推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 一直以來，對于如何吃到“放心中藥”一直是業(yè)界難題，對于國家取消中藥GAP認證，參加十二屆全國人大四次會議的全國人大代表閆希軍認為：“這并不影響中藥質(zhì)量的保證，只要建立藥產(chǎn)品全產(chǎn)業(yè)鏈質(zhì)量追溯體系?！?/p>
2016年2月3日，國務(wù)院印發(fā)《關(guān)于取消13項國務(wù)院部門行政許可事項的決定》(國發(fā)〔2016〕10號)，取消中藥材生產(chǎn)質(zhì)量管理規(guī)范(GAP)認證。中藥產(chǎn)品上游質(zhì)量控制全部下放給企業(yè)，迫切需要一套支持全產(chǎn)業(yè)鏈、具有公信力的質(zhì)量追溯體系來統(tǒng)一監(jiān)督中藥產(chǎn)品各環(huán)節(jié)產(chǎn)品質(zhì)量。
閆希軍稱：“因為15年前，教會了我們農(nóng)民怎么能夠種藥，怎么能夠按照標(biāo)準(zhǔn)種藥，我們今天取消了GAP認證，更重要的質(zhì)量要后移，就在中藥材在收儲加工過程中:一，要加強檢驗，首先檢驗它的真?zhèn)螁栴}，比如說中藥是不是NDA條碼進行鑒定,二，要有安全性評價,里面的它的有效物質(zhì)的含量如何，通過這樣的評價就可以解決，再加上我們現(xiàn)代化全程追溯的物流體系，通過這些物流體系，貫通全程追溯，就是能夠追溯源頭，過程客觀，責(zé)任可追，這樣的話全產(chǎn)業(yè)鏈可以推動中醫(yī)藥有效的發(fā)展?！?/p>
